Pfizer, Inc. (NYSE: PFE)

Sector: Medical

Current Price : $28.96

52 Week Low
$21.6052 Week High
$31.06

Charts

Technical Charts

Analyst

Analyst Ratings

Analyst Estimates

Sales Estimates

Ratios

Financial Ratios

Technicals

Press Releases
The Straight Truth, Investing in GRPN, INTC and PFE
Strategy Behind Our Success, We Get in Early: BSX, AINV, PFE and SPF
Special Situation Coming Soon, a Look Inside PFE, F, BSX and FB
Special Offer for Shareholders of PFE, DELL, GE and BSX
Squawk Box Stocks Reports On: Nokia Corporation (NYSE: NOK), Advanced Micro Devices, Inc. (NYSE: AMD), Zynga, Inc. (NASDAQ: ZNGA), Pfizer Inc. (NYSE: PFE)
Pfizer Announces 11 Abstracts for Tofacitinib to Be Presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting
Before the Crowd, How We Found BAC, XOM, ACT and PFE
Key to Success, How to Profit: PFE, INTC, DIS and PCLN
Pain Therapeutics Files Form 8-K Regarding Correspondence From Pfizer, Inc.
Accelrys and Pfizer Extend Agreement for Global Deployment of Scientific Innovation Lifecycle Management Software
Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation
Facing Off Against Counterfeit Online Pharmacies: Pfizer Launches New Purchasing Website To Help Alleviate the Guesswork Around Buying Legitimate Viagra? (sildenafil citrate) Online
Free Research Reports on IVZ, MGAM, PFE and VSH Issued by the Bedford Report
Pfizer Reports First-Quarter 2013 Results
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevenar 13 In Adults Aged 18 To 49 Years
The Reason It Trades, What's Moving PXP, PFE, MMM and FCX
Pfizer Receives CHMP Negative Opinion Regarding Marketing Authorization In Europe For Rheumatoid Arthritis Treatment XELJANZ? (tofacitinib citrate)
Pfizer Hosts Annual Meeting Of Shareholders
Pain Therapeutics Reports Q1 2013 Financial Results
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Wyeth of Class Action Lawsuit and the Deadline of June 11, 2013 to Seek a Lead Plaintiff Position -- PFE
Brower Piven Encourages Investors Who Purchased 20,000 or More Shares of Wyeth Common Stock to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the June 11, 2013 Lead Plaintiff Deadline
Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders
Perfect Trade Setups, How to Play PFE and JPM
Free Research Reports on CVX, PCS, PFE and PSUN Issued by the Bedford Report
Pfizer's Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
StockCall Scrutinizes Pfizer, Merck & Co., Johnson & Johnson, and AbbVie
Acura Pharmaceuticals Awarded U.S. Patent for Abuse Deterrent Drug Formulations
Advil? Launches Advil? Relief in Action Campaign Celebrating Active Volunteers Who Don't Let Pain Hold Them Back
Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles for Recoupment Policies Covering Major Compliance Failures
Free Research Reports on D, PFE, SWY and VZ Issued by the Bedford Report
S&P 500 Reaches a New All-Time High -- Index Finally Recovers From the Financial Crisis
Pfizer's BOSULIF? (bosutinib) Receives Conditional Marketing Authorization From The European Commission
Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts
Special Offer for Shareholders of PFE, ALU, YHOO and F
The Reason It Trades, What's Moving KRFT, PSE, PFE and INTC
XELJANZ? (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)
Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP
Perfect Trade Setups, How to Play GE, PFE, CAT and QCOM
The Real Story Behind CAH, PFE and EBAY
UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease
Start Making Profits Now With T, PFE and QCOM
Improving Lives: Breakthroughs & Collaborations - Research Report on Pfizer, Merck, Bristol-Myers Squibb, J&J and Lilly
A Forward Look, The Year Ahead - Research Report on Pfizer Inc., The Boeing Company, Lockheed Martin Corporation, Barclays PLC and HSBC Holdings plc
StockCall Study on Merck & Co., Pfizer, Johnson & Johnson, and AbbVie
Secrets to Making Money in MSFT, AIG, PFE and XOM
New trial results support treatment with Inspra (eplerenone) within first 24 hours of symptoms, in addition to standard therapy, in patients with acute STEMI without heart failure.
Strategy Behind Our Success, We Get in Early: PFE, GE, IBM and CELG
Before the Crowd, How We Found INTC, JCP, PFE and GE
United States Patent & Trademark Office Grants Pfizer Reissue Patent For Celebrex? (celecoxib capsules)
Key to Success, How to Profit: PFE, MO, LNKD and TXN
Next Week's Trade Setups, What's in Store for PFE, ABT, MDLZ and COF
The Real Story Behind MS, PFE, HFC and QCOM
Today's Technical View on PFE, JNJ and MRK
Opportunity Knocks, Timing Is Everything With T, CELG, PFE and VLO
Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC, Pfizer and Infinity Pharmaceuticals
The Year Ahead, A Forward Look - Research Report on General Mills, Inc., GlaxoSmithKline plc., Pfizer Inc., The Coca-Cola Company and Dr. Pepper Snapple Group, Inc.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Earnings Help Fuel S&P 500 Index Rally -- S&P 500 Index Tops 1500 Mark for the First Time in 5 Years
Turn Timing Into Profits With INTC, PFE, NWSA and AFFY
Leading Pharmaceutical Companies Mid-day Trading with Mixed Results and also New Patent News Announced for Crown Marketing
Market Movers, Money Makers -- Start Now With YHOO, JNJ, PFE and EBAY
Were You in Early on GE, PFE, DELL and DIS
Did You Miss PPG, VMED, PFE and AKAM
Pain Therapeutics Reports 2012 Financial Results
Pfizer Inc. Issues Statement on ZoetisTM IPO
Pfizer and Eli Lilly Rise on Fourth Quarter Earnings -- S&P 500 Index Hovers Near 5-Year Highs
Special Situation Coming Soon, a Look Inside PFE, S, ESRX and UN
Pfizer Wins RAPAMUNE? Patent Case in Delaware District Court
Free Research Reports on ANAC, KERX, LXK and PFE Issued by the Bedford Report
Key to Success, How to Profit: PBR, PFE, QCOM and RF
Pfizer Reports Fourth-Quarter and Full-Year 2012 Results; Provides 2013 Financial Guidance
Pfizer Receives FDA Approval For The Use Of Prevnar 13 In Vaccine-Naive Children And Adolescents Aged 6 Years Through 17 Years For The Prevention Of Invasive Pneumococcal Disease
ChapStick? Sessions Applies a Spotlight on Musically Talented Lips
Study Shows Higher Dose Of Toviaz? (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder
The Reason It Trades, What's Moving AMD, COH, GE and PFE
Pfizer Announces Top-Line Efficacy Results From A Phase 4 Study Of PRISTIQ? (desvenlafaxine) For The Treatment Of Major Depressive Disorder (MDD) In Adults
Data Shows Peak Cold and Flu Season is Here for Chicago
Data Shows Peak Cold and Flu Season is Here for Philadelphia
Top Pharmaceutical Stocks for 2013: Crown Marketing Inc., Pfizer Inc., Merck & Co. Inc., and Eli Lilly and Company
Technical Review: New Releases from Drug Maker Majors Cushion Against Patent Cliff Effects
Perfect Trade Setups, How to Play BSX, NBY, BTX and PFE
Pfizer Receives European Approval To Expand Use Of Prevenar 13 To Older Children And Adolescents Aged 6 To 17 Years For The Prevention Of Pneumococcal Disease
The Real Story Behind ABT, HLF, PFE and GSK
Most Active Stocks as The Market Starts The New Year Off on a Bull run!
S&P 500 Index Gains the Most Since 2009 -- Fiscal Cliff Likely to Be Avoided
Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS? (apixaban)
Friday's Most Active - SPY, PFE, MS and FITB
Perfect Trade Setups, How to Play S, PFE, GE and INTC
ELIQUIS? (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation
Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And Commercialize Subcutaneous Biologics Using Recombinant Human Hyaluronidase
Humedica and Pfizer Form Strategic Alliance
Pfizer Invites Public To View And Listen To Webcast Of January 29 Conference Call With Analysts
The Real Story Behind PFE, LFVN, AMRN and HOV
The Real Story Behind YHOO, PFE, T and C
Pfizer Declares First-Quarter 2013 Dividend
U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis
Free Research Reports on LMT, PFE, VZ and ZIOP Issued by the Bedford Report
Strategy Behind Our Success, We Get in Early: AMRN, VRX, TEVA and PFE
New Evidence in IsoRay's Brain Cancer Treatment

iStock Rating

Pfizer, Inc. (NYSE: PFE)

Sector: Medical

Company

Community

Analysis

Charts

Analyst

Ratios